{"id":41506,"date":"2015-01-14T16:37:02","date_gmt":"2015-01-14T15:37:02","guid":{"rendered":"http:\/\/www.r-biopharm.com\/?p=41506"},"modified":"2017-10-27T14:03:42","modified_gmt":"2017-10-27T12:03:42","slug":"medikamenten-monitoring-von-infliximab-remicade","status":"publish","type":"post","link":"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/","title":{"rendered":"Therapeutisches Medikamenten-Monitoring von Infliximab (Remicade\u00ae)"},"content":{"rendered":"<p><strong>RIDASCREEN\u00ae IFX Monitoring ist ein Enzymimmunoassay zum quantitativen Nachweis von Infliximab (IFX, Remicade\u00ae, anti-TNF\u03b1) in humanem Serum und Plasma.<\/strong><\/p>\n<p>Er ist die kommerzialisierte CE-registrierte Version des home-brew Assays der KU Leuven, die weltweit f\u00fchrend im Bereich des therapeutischen Medikamenten-Monitorings ist. Dieser wurde ebenfalls in der TAXIT-Studie* verwendet, die den positiven Effekt von TMD auf Therapie- und Kostenoptimierung belegt.<\/p>\n<p><!--more--><\/p>\n<h2>Medikamenten-Monitoring von Infliximab<\/h2>\n<p>Infliximab (Remicade\u00ae) wird f\u00fcr die Behandlung von entz\u00fcndlichen Erkrankungen wie Morbus Crohn und Colitis ulcerosa\u00a0 eingesetzt. Aufgrund individueller Pharmakokinetik zeigen unterschiedliche Personen bei identischer Dosierung unterschiedliche <strong>IFX-Medikamentenspiegel<\/strong>. Um wirksam zu sein, muss jedoch eine bestimmte Medikamentenkonzentration im Blut des Patienten vorliegen.<\/p>\n<h2>Testen von IFX-Medikamentenkonzentrationen<\/h2>\n<p>Durch therapeutisches\u00a0 Medikamenten-Monitoring kann diese \u00fcberpr\u00fcft werden und so die <strong>Dosierung optimal auf die Bed\u00fcrfnisse des Patienten<\/strong> <strong>eingestellt<\/strong> werden.Hierzu wird jeweils vor der n\u00e4chsten Infusion die IFX-Medikamentenkonzentrationen im Blut getestet (Talspiegelkonzentration).<\/p>\n<p>* Vande Casteele N. et al, OP001 Randomised controlled trial of drug level versus clinically based dosing of Infliximab maintenance therapy in IBD: Final results of the TAXIT study. UEG Journal 2013.<\/p>\n<p><strong>Weitere Inforamtionen:<\/strong><\/p>\n<ul>\n<li><a href=\"http:\/\/www.r-biopharm.com\/de\/produkte\/klinische-diagnostik\/gastroenterologie\/entzuendliche-darmerkrankungen\/item\/ridascreen-ifx-monitoring\">RIDASCREEN<span class=\"regs\">\u00ae<\/span> IFX Monitoring Webseite<\/a><\/li>\n<li><a href=\"http:\/\/www.r-biopharm.com\/wp-content\/uploads\/41229\/2014-12_RS_IFX_Monitoring_4-Seiter_DE_LowRes.pdf\">Produktinformation<\/a><\/li>\n<li><a href=\"http:\/\/www.r-biopharm.com\/wp-content\/uploads\/41229\/G09041_RIDASCREEN-IFX-Monitoring_2014-12-18_DT.pdf\">Durchf\u00fchrungsanleitung<\/a><\/li>\n<\/ul>\n<p>Kontakt: <strong>ifx&#64;r-bi&#111;&#112;&#104;&#97;&#114;&#109;&#46;&#100;&#101;<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>RIDASCREEN\u00ae IFX Monitoring ist ein Enzymimmunoassay zum quantitativen Nachweis von Infliximab (IFX, Remicade\u00ae, anti-TNF\u03b1) in humanem Serum und Plasma. Er ist die kommerzialisierte CE-registrierte Version des home-brew Assays der KU Leuven, die weltweit f\u00fchrend im Bereich des therapeutischen Medikamenten-Monitorings ist. Dieser wurde ebenfalls in der TAXIT-Studie* verwendet, die den positiven Effekt von TMD auf Therapie- [&hellip;]<\/p>\n","protected":false},"author":27,"featured_media":86888,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[239,252],"tags":[142,198],"class_list":["post-41506","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gastroenterologie","category-therapeutisches-drug-monitoring","tag-ifx","tag-tdm"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Therapeutisches Medikamenten-Monitoring von Infliximab (Remicade\u00ae) (de) - Clinical Diagnostics<\/title>\n<meta name=\"description\" content=\"RIDASCREEN\u00ae IFX Monitoring von Infliximab (IFX, Remicade\u00ae, anti-TNF\u03b1) in humanem Serum und Plasma. Erfahren Sie hier mehr \u00fcber Monitoring von Infliximab.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Therapeutisches Medikamenten-Monitoring von Infliximab (Remicade\u00ae) (de) - Clinical Diagnostics\" \/>\n<meta property=\"og:description\" content=\"RIDASCREEN\u00ae IFX Monitoring von Infliximab (IFX, Remicade\u00ae, anti-TNF\u03b1) in humanem Serum und Plasma. Erfahren Sie hier mehr \u00fcber Monitoring von Infliximab.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical Diagnostics\" \/>\n<meta property=\"article:published_time\" content=\"2015-01-14T15:37:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-10-27T12:03:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/01\/2015-01_IFX_Montioring_NEWS-3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"690\" \/>\n\t<meta property=\"og:image:height\" content=\"252\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Janine Dege\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Janine Dege\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/medikamenten-monitoring-von-infliximab-remicade\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/medikamenten-monitoring-von-infliximab-remicade\\\/\"},\"author\":{\"name\":\"Janine Dege\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/#\\\/schema\\\/person\\\/7bcf9ead36ba80c48ad551e786874e6f\"},\"headline\":\"Therapeutisches Medikamenten-Monitoring von Infliximab (Remicade\u00ae)\",\"datePublished\":\"2015-01-14T15:37:02+00:00\",\"dateModified\":\"2017-10-27T12:03:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/medikamenten-monitoring-von-infliximab-remicade\\\/\"},\"wordCount\":192,\"image\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/medikamenten-monitoring-von-infliximab-remicade\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/wp-content\\\/uploads\\\/2015\\\/01\\\/2015-01_IFX_Montioring_NEWS-3.jpg\",\"keywords\":[\"IFX\",\"TDM\"],\"articleSection\":[\"Gastroenterologie\",\"Therapeutisches Drug Monitoring\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/medikamenten-monitoring-von-infliximab-remicade\\\/\",\"url\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/medikamenten-monitoring-von-infliximab-remicade\\\/\",\"name\":\"Therapeutisches Medikamenten-Monitoring von Infliximab (Remicade\u00ae) (de) - Clinical Diagnostics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/medikamenten-monitoring-von-infliximab-remicade\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/medikamenten-monitoring-von-infliximab-remicade\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/wp-content\\\/uploads\\\/2015\\\/01\\\/2015-01_IFX_Montioring_NEWS-3.jpg\",\"datePublished\":\"2015-01-14T15:37:02+00:00\",\"dateModified\":\"2017-10-27T12:03:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/#\\\/schema\\\/person\\\/7bcf9ead36ba80c48ad551e786874e6f\"},\"description\":\"RIDASCREEN\u00ae IFX Monitoring von Infliximab (IFX, Remicade\u00ae, anti-TNF\u03b1) in humanem Serum und Plasma. Erfahren Sie hier mehr \u00fcber Monitoring von Infliximab.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/medikamenten-monitoring-von-infliximab-remicade\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/medikamenten-monitoring-von-infliximab-remicade\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/medikamenten-monitoring-von-infliximab-remicade\\\/#primaryimage\",\"url\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/wp-content\\\/uploads\\\/2015\\\/01\\\/2015-01_IFX_Montioring_NEWS-3.jpg\",\"contentUrl\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/wp-content\\\/uploads\\\/2015\\\/01\\\/2015-01_IFX_Montioring_NEWS-3.jpg\",\"width\":690,\"height\":252},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/medikamenten-monitoring-von-infliximab-remicade\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Therapeutisches Medikamenten-Monitoring von Infliximab (Remicade\u00ae)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/\",\"name\":\"Clinical Diagnostics\",\"description\":\"A Division of the R-Biopharm Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/#\\\/schema\\\/person\\\/7bcf9ead36ba80c48ad551e786874e6f\",\"name\":\"Janine Dege\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4cbca03fc07097934a5058c95fc3b1baaf182a156a174233532f9c3887c50eee?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4cbca03fc07097934a5058c95fc3b1baaf182a156a174233532f9c3887c50eee?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4cbca03fc07097934a5058c95fc3b1baaf182a156a174233532f9c3887c50eee?s=96&d=mm&r=g\",\"caption\":\"Janine Dege\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Therapeutisches Medikamenten-Monitoring von Infliximab (Remicade\u00ae) (de) - Clinical Diagnostics","description":"RIDASCREEN\u00ae IFX Monitoring von Infliximab (IFX, Remicade\u00ae, anti-TNF\u03b1) in humanem Serum und Plasma. Erfahren Sie hier mehr \u00fcber Monitoring von Infliximab.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/","og_locale":"de_DE","og_type":"article","og_title":"Therapeutisches Medikamenten-Monitoring von Infliximab (Remicade\u00ae) (de) - Clinical Diagnostics","og_description":"RIDASCREEN\u00ae IFX Monitoring von Infliximab (IFX, Remicade\u00ae, anti-TNF\u03b1) in humanem Serum und Plasma. Erfahren Sie hier mehr \u00fcber Monitoring von Infliximab.","og_url":"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/","og_site_name":"Clinical Diagnostics","article_published_time":"2015-01-14T15:37:02+00:00","article_modified_time":"2017-10-27T12:03:42+00:00","og_image":[{"width":690,"height":252,"url":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/01\/2015-01_IFX_Montioring_NEWS-3.jpg","type":"image\/jpeg"}],"author":"Janine Dege","twitter_misc":{"Verfasst von":"Janine Dege","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/#article","isPartOf":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/"},"author":{"name":"Janine Dege","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/7bcf9ead36ba80c48ad551e786874e6f"},"headline":"Therapeutisches Medikamenten-Monitoring von Infliximab (Remicade\u00ae)","datePublished":"2015-01-14T15:37:02+00:00","dateModified":"2017-10-27T12:03:42+00:00","mainEntityOfPage":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/"},"wordCount":192,"image":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/#primaryimage"},"thumbnailUrl":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/01\/2015-01_IFX_Montioring_NEWS-3.jpg","keywords":["IFX","TDM"],"articleSection":["Gastroenterologie","Therapeutisches Drug Monitoring"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/","url":"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/","name":"Therapeutisches Medikamenten-Monitoring von Infliximab (Remicade\u00ae) (de) - Clinical Diagnostics","isPartOf":{"@id":"https:\/\/clinical.r-biopharm.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/#primaryimage"},"image":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/#primaryimage"},"thumbnailUrl":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/01\/2015-01_IFX_Montioring_NEWS-3.jpg","datePublished":"2015-01-14T15:37:02+00:00","dateModified":"2017-10-27T12:03:42+00:00","author":{"@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/7bcf9ead36ba80c48ad551e786874e6f"},"description":"RIDASCREEN\u00ae IFX Monitoring von Infliximab (IFX, Remicade\u00ae, anti-TNF\u03b1) in humanem Serum und Plasma. Erfahren Sie hier mehr \u00fcber Monitoring von Infliximab.","breadcrumb":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/#primaryimage","url":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/01\/2015-01_IFX_Montioring_NEWS-3.jpg","contentUrl":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/01\/2015-01_IFX_Montioring_NEWS-3.jpg","width":690,"height":252},{"@type":"BreadcrumbList","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/medikamenten-monitoring-von-infliximab-remicade\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clinical.r-biopharm.com\/de\/"},{"@type":"ListItem","position":2,"name":"Therapeutisches Medikamenten-Monitoring von Infliximab (Remicade\u00ae)"}]},{"@type":"WebSite","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#website","url":"https:\/\/clinical.r-biopharm.com\/fr\/","name":"Clinical Diagnostics","description":"A Division of the R-Biopharm Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clinical.r-biopharm.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/7bcf9ead36ba80c48ad551e786874e6f","name":"Janine Dege","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/4cbca03fc07097934a5058c95fc3b1baaf182a156a174233532f9c3887c50eee?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4cbca03fc07097934a5058c95fc3b1baaf182a156a174233532f9c3887c50eee?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4cbca03fc07097934a5058c95fc3b1baaf182a156a174233532f9c3887c50eee?s=96&d=mm&r=g","caption":"Janine Dege"}}]}},"_links":{"self":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/41506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/comments?post=41506"}],"version-history":[{"count":1,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/41506\/revisions"}],"predecessor-version":[{"id":87217,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/41506\/revisions\/87217"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/media\/86888"}],"wp:attachment":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/media?parent=41506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/categories?post=41506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/tags?post=41506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}